RemeGen Co (FRA:REG) Debt-to-Revenue : 1.62 (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is RemeGen Co Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

RemeGen Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €127.5 Mil. RemeGen Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €179.6 Mil. RemeGen Co's annualized Revenue for the quarter that ended in Jun. 2024 was €189.4 Mil. RemeGen Co's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 1.62.

RemeGen Co Debt-to-Revenue Historical Data

The historical data trend for RemeGen Co's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Debt-to-Revenue Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

N/A

0.07

0.22

1.17

RemeGen Co Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Revenue	Get a 7-Day Free Trial							0.13	0.20	0.84	0.96	1.62

Competitive Comparison of RemeGen Co's Debt-to-Revenue

For the Biotechnology subindustry, RemeGen Co's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Debt-to-Revenue falls into.

RemeGen Co Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

RemeGen Co's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(44.272	+	117.545)	/	138.205
	=	1.17

RemeGen Co's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(127.527	+	179.56)	/	189.434
	=	1.62

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.

RemeGen Co Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (FRA:REG) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

REGMF:USA 09995:Hong Kong 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

https://www.remegen.com

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat major diseases such as autoimmune diseases, oncology, and ophthalmology. The company has its operations in China and the USA and derives the majority of its revenue from China.